Tenapanor

Tenapanor
Names
Trade namesIbsrela
Other namesTenapanor hydrochloride
IUPAC name
  • N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis([(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide)
Clinical data
Drug classNHE3 inhibitors
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: N (Not classified yet)
    Routes of
    use    		By mouth
    External links
    AHFS/Drugs.comMonograph
    Legal
    License data
    Legal status
    Chemical and physical data
    FormulaC50H66Cl4N8O10S2
    Molar mass1145.04 g·mol−1
    3D model (JSmol)
    SMILES
    • CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C
    InChI
    • InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
    • Key:DNHPDWGIXIMXSA-CXNSMIOJSA-N

    Tenapanor, sold under the brand name Ibsrela, is a medication used to treat irritable bowel syndrome with constipation (IBS-C).[1] It is taken by mouth.[1]

    Common side effects include diarrhea, abdominal swelling, and lightheadedness.[1] Use in pregnancy and breastfeeding is believed to be safe.[1] It acts by blocking the sodium-proton exchanger NHE3 there by decreasing the uptake of sodium by the intestines.[1]

    Tenapanor was approved for medical use in the United States in 2019.[1] As of 2021; however, it is not yet in pharmacies.[2] As of 2021 it is not approved in Europe or the United Kingdom.[3]

    Medical uses

    It is used for irritable bowel syndrome with constipation (IBS-C).[4]

    Dosage

    It is usually taken at a dose of 50 mg two times per day.[1]

    History

    The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5]

    References

    1. 1 2 3 4 5 6 7 "Tenapanor Monograph for Professionals". Drugs.com. Archived from the original on 27 January 2021. Retrieved 25 September 2021.
    2. ↑ "Ibsrela Prices and Ibsrela Coupons - GoodRx". GoodRx. Retrieved 25 September 2021.
    3. ↑ "Tenapanor". SPS - Specialist Pharmacy Service. 26 May 2017. Archived from the original on 23 July 2017. Retrieved 25 September 2021.
    4. ↑ "Drug Trials Snapshots: Ibsrela". U.S. Food and Drug Administration (FDA). 27 September 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.Public Domain This article incorporates text from this source, which is in the public domain.
    5. ↑ "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Archived from the original on 16 September 2020. Retrieved 15 September 2020.
    Identifiers:
    • "Tenapanor". Drug Information Portal. U.S. National Library of Medicine (NLM). Archived from the original on 29 August 2021. Retrieved 1 July 2021.
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.